KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH 11–13) that retains potent NF-κB and pro-inflammatory cytokine modulation without melanogenic pigmentary activity.
Scientific Profile & Research Key Points: KPV
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH 11–13) that retains potent NF-κB and pro-inflammatory cytokine modulation without melanogenic pigmentary activity.
Active Batch Release Specifications (Lot SL-2026-138)
Analytical release verification for current KPV (10 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-138 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile PBS (>20 mg/mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate solution at 2°C–8°C for up to 28 days.
KPV — Technical Questions & Answers
What is the molar concentration when reconstituting KPV (10 mg) in 2.0 mL?
Reconstituting the full 10 mg vial of KPV (MW 342.43 g/mol) in 2.0 mL of diluent produces a 5.00 mg/mL stock solution — equivalent to approximately 14.60 mM (14,602 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does KPV's counterion stoichiometry affect assay mass calculations?
KPV (CAS 67727-97-3, formula C16H30N4O4) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify KPV Lot SL-2026-138 and what pathway does it target?
Lot SL-2026-138 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 342.43 g/mol. In preclinical literature, KPV targets NF-κB nuclear translocation & PepT1-mediated mucosal inflammatory pathways (Dalmasso G. et al., Gastroenterology (2008) — PepT1-mediated tripeptide KPV anti-inflammatory signaling (PMID: 18061177)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
BPC-157 vs TB-500 vs KPV: Tendon Repair, Actin & Inflammatory Pathways
A comparative analysis of Body Protection Compound-157 (pentadecapeptide) and Thymosin Beta-4 active fragment TB-500. Differences in VEGF signaling, actin sequestration, and combined laboratory models.
KPV Tripeptide (Lys-Pro-Val): C-Terminal Alpha-MSH Chemistry, NF-κB Inactivation, and Gut Mucosal Integrity
A biochemical review of the KPV tripeptide (Lys-Pro-Val). Transport via PepT1, nuclear translocation blockade of NF-κB p65, cytokine reduction (TNF-α, IL-6), and mucosal barrier restoration assays.
How to Read a Peptide Certificate of Analysis (COA): Step-by-Step Breakdown
A practical guide for researchers. How to analyze HPLC chromatograms, verify retention time, interpret mass spec m/z peaks, evaluate counterion salt ratios, and spot fraudulent documents.
Related Recovery & Tissue Repair Compounds
View category →